Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Worldwide Chairman Paul Stoffels On Precompetitive Alliances, Patent Pools And Tropical Drugs: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

For Paul Stoffels, worldwide chairman, pharmaceuticals at Johnson & Johnson, innovation has been a long-time passion. Stoffels is regarded as a specialist in HIV therapies. In 1997, he left Janssen Research Foundation to become the CEO of Tibotec-Virco, which he transformed from a technology-based research company into an integrated R&D organization focused on the discovery and development of new drugs and diagnostics for HIV/AIDS and infectious diseases.

You may also be interested in...



Australia’s Atomo Seeks Pharma Partners For HIV, Malaria Diagnostics

Australia-based firm Atomo wants to partner with a multinational pharmaceutical company to develop an easy to use finger-prick unit to test for HIV infection in rural populations. Atomo is already working with Africa’s Desmond Tutu HIV Foundation and has been recognized in industry awards for design and innovation.

Market Access Strategies: Pending Approvals, J&J Plans Cautious Steps For Access To Anti-TB Drug Bedaquiline

In an interview, Janssen Chairman Paul Stoffels discusses market access issues related to bedaquiline and J&J’s recent decision to free up patents on its HIV therapy Prezista.

Market Access Strategies: Pending Approvals, J&J Plans Cautious Steps For Access To Anti-TB Drug Bedaquiline

In an interview with PharmAsia News, Janssen Chairman Paul Stoffels discusses market access issues related to bedaquiline and J&J’s recent decision to free up patents on its HIV therapy Prezista.

Related Content

UsernamePublicRestriction

Register

PS140995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel